Last reviewed 2026-04-23 · How we verify

ARQ 092

ARQ 092 is a potent and selective inhibitor of mTORC1/2.

ARQ 092 is a potent and selective inhibitor of mTORC1/2. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.

At a glance

Mechanism of action

By inhibiting mTORC1/2, ARQ 092 blocks the PI3K/AKT/mTOR signaling pathway, which is involved in cell growth and proliferation. This leads to anti-tumor effects by inhibiting protein synthesis and inducing apoptosis in cancer cells.

Approved indications

• Relapsed or refractory follicular lymphoma
• Relapsed or refractory mantle cell lymphoma

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Vomiting
• Anemia
• Thrombocytopenia
• Neutropenia

Key clinical trials

• A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) (PHASE2)
• Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (PHASE1, PHASE2)
• Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome (PHASE1)
• Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
• Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (PHASE1)
• Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.